EFFECT OF COMPLEMENTARY DRUG REGIMEN ON CORONARY ARTERIOSCLEROSIS

补充药物疗法对冠状动脉硬化的影响

• 批准号: 3741087
• 负责人: JOHN P KANE
• 金额: --
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3741087
• 关键词: angiography; antihypercholesterolemic agent; antihyperlipoproteinemic agent; arteriosclerosis; atherosclerotic plaque; blood chemistry; cholesterol; combination chemotherapy; computer assisted diagnosis; coronary disorder; drug screening /evaluation; free fatty acids; heart disorder chemotherapy; human subject; human therapy evaluation

These studies are a continuation of protocol #20-1, except for the addition of probucol as one of the drugs. Since we can now normalize LDL cholesterol in patients with heterozygous familial hypercholesterolemia using a combined drug regimen, we are testing the regimen's ability to shrink atherosclerotic plaques as measured by computerized angiography. Patients are studied in the GCRC for the effect of treatment on levels of plasma free fatty acid.

这些研究是方案 #20-1 的延续，除了 添加普罗布考作为药物之一。 既然我们现在可以使 LDL 正常化 杂合子家族性高胆固醇血症患者的胆固醇 使用联合药物治疗方案，我们正在测试该治疗方案的能力 通过计算机血管造影测量，缩小动脉粥样硬化斑块。 GCRC 研究患者治疗对水平的影响 血浆游离脂肪酸。